智通财经网·2026-01-28 06:26Group 1 - The core focus of the 2026 JPM Conference is on the strategic importance of IO (Immuno-Oncology) and ADC (Antibody-Drug Conjugates) in the oncology sector, with a significant emphasis on combination therapies [1] - The conference, held from January 12 to 15, 2026, in San Francisco, is recognized as a key event for insights into new drug development trends, capital flows, and business development collaborations in the healthcare industry [1] - Major multinational corporations (MNCs) are prioritizing second-generation IO and ADC, with a notable contribution from domestic innovations, particularly the introduction of sac-TMT by Merck as a focal point in oncology development [2] Group 2 - The exploration of combination therapies involving IO and ADC is accelerating, with multiple clinical trials underway, including 16 Phase III trials for sac-TMT and 4 Phase III trials for PD-(L)1/VEGF dual antibodies by Pfizer [2] - The year 2026 is identified as a pivotal year for the combination of IO and ADC, with expectations for increased demand for ADCs as they gain a core position in current cancer treatments [3] - Key players in the ADC market include companies such as Kangfang Biopharma, Sanofi, Rongchang Biopharma, and others, indicating a competitive landscape for ADC development [3]